Marker Therapeutics, Inc. annual report, FY2011

Business context and reporting period

This filing is TapImmune Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed in April 2012. The request metadata names Marker Therapeutics, Inc. and “2011 Q4”; those do not match the issuer and annual reporting period stated in the filing. TapImmune was a development-stage biotechnology company with no marketed products or revenue, developing TAP-based cancer and infectious-disease vaccine technologies.

Financial performance and position

Gross profit and operating margins are not meaningful because the company reported no revenue. At December 31, 2011, current assets were $307,921 and current liabilities were $3.801 million. MD&A reports a working-capital deficit of $3.493 million; Note 1 gives $2.175 million excluding derivative liabilities. Convertible notes had a carrying value of $998,790; the balance sheet also reports $1.318 million of warrant derivative liabilities, a $100,000 promissory note in default, and $322,905 due to related parties. The filing provides no clear consolidated total-debt figure distinct from these liabilities.

Changes versus the prior comparable period

• Net loss narrowed by about 43%, while operating expenses declined about 39%, primarily due to lower stock-based management compensation, professional fees, interest and financing charges, and R&D spending.
• Operating cash use increased about 42%, despite the lower net loss. Non-cash stock compensation and derivative fair-value changes significantly affected reported earnings.
• Cash increased by approximately $227,000, supported by financing inflows, including private placements and convertible notes. Common shares outstanding rose from 40.3 million at year-end 2010 to 52.1 million at year-end 2011.
• The company restated 2010 financial statements, reclassifying certain warrants as derivative liabilities rather than equity because specified transactions could require cash settlement. Restated 2010 net loss was $3.533 million, $1.558 million lower than previously reported; the restatement did not change 2010 operating cash use.

Outlook, risks and unusual items

• Management estimated approximately $5 million of funding was needed over the next 12 months for operations and planned development. No financing commitments had been secured; failure to raise capital could force the company to scale back or abandon its plans. The auditor and management cited substantial doubt about the company’s ability to continue as a going concern.
• The FDA had approved an IND for a Mayo Clinic HER2/neu breast-cancer Phase I trial. The filing describes patient dosing as expected in 2012, but gives inconsistent timing (first quarter, end of second quarter, and second quarter in different passages). Smallpox-vaccine animal studies were underway, with feasibility work expected to conclude in 2012.
• Management estimated roughly $5 million to fund preclinical and clinical programs in cancer and infectious disease. The company had no product revenue, no regular payroll employees, and depended on outside financing, partners, and collaborators.
• Clinical development, regulatory approval, manufacturing, intellectual-property protection, competition, key-person dependence, and financing are material risks. Product-liability insurance was not maintained because products were not yet being sold.
• Crucell obligations of $259,752 were accrued and delinquent; Crucell could cancel the license, and renegotiation was uncertain. The $100,000 promissory note matured in July 2011 and remained in default at year-end. Some U.S. tax returns had not been filed; possible penalties and interest were not reliably measurable.
• Derivative warrant liabilities were valued using Level 3 assumptions, including 199% volatility; changes in estimated fair value affected earnings and may not indicate cash performance. Disclosure controls were deemed ineffective, and management identified material weaknesses in financial reporting controls. The audit firm’s report expressed a going-concern uncertainty and did not attest to internal-control effectiveness.
• After year-end, the company issued shares in March 2012 to settle debt and accrued management compensation, raised $110,000 in a private placement, and settled $118,466 of note interest with shares.

Key facts investors should verify

1. Whether the company obtained the approximately $5 million of financing it said was needed, and its subsequent cash runway and going-concern status.
2. The actual start date, enrollment, safety findings, and milestones for the Mayo Clinic HER2/neu trial, given the filing’s inconsistent timing statements.
3. The status and terms of the delinquent Crucell obligations, the defaulted promissory note, and other secured convertible debt.
4. The warrant-liability valuation, settlement features, potential cash obligations, and dilution from outstanding shares, options, and warrants.
5. Remediation of the disclosed control weaknesses and completion of outstanding tax filings.
6. The correct issuer and reporting period for the requested summary: this document identifies TapImmune Inc. and fiscal 2011, not Marker Therapeutics, Inc. or a standalone fourth-quarter report.